Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 7/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | UNG | P13051 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23110028 | 0.82 | PRMT6 (0.46) | TP53THRBPRMT6ALDH1A1LMNA | |
| SCHEMBL14259479 | 0.78 | TP53 (0.46) | TP53THRBPRMT6ALDH1A1LMNA | |
| SCHEMBL146369 | 0.77 | TP53 (0.61) | TP53THRBPRMT6ALDH1A1LMNA | |
| SCHEMBL6852425 | 0.77 | ALDH1A1 (0.52) | MAOAMAOBALDH1A1NPC1RAB9A | |
| SCHEMBL12155125 | 0.77 | TP53 (0.45) | TP53THRBPRMT6ALDH1A1LMNA | |
| SCHEMBL1854966 | 0.76 | TAAR1 (0.46) | TP53THRBMAOBPRMT6ALDH1A1 | |
| SCHEMBL25128132 | 0.76 | TP53 (0.44) | TP53THRBMAOAMAOBPRMT6 | |
| SCHEMBL1733252 | 0.76 | TP53 (0.44) | TP53THRBPRMT6ALDH1A1LMNA | |
| SCHEMBL20546828 | 0.75 | MAOA (0.59) | MAOAMAOBALDH1A1BRD4NPC1 | |
| SCHEMBL20546750 | 0.75 | MAOA (0.62) | TP53MAOAMAOBALDH1A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183264-B2 | Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same | Eisai R&D Managment Co., Ltd. (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2065377-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-2065377-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2065377-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | disclosed |
| EP-2065377-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099718-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROARYL RING, AND ANTIFUNGAL AGENT COMPRISING THE SAME | ERG28, CBR3, CBR1 | TP53 3294/4885THRB 4473/4885MAOA 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.